Daiichi Sankyo Company Limited (JP:4568)
:4568
Want to see JP:4568 full AI Analyst Report?
Top Page
Daiichi Sankyo Company
(4568)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥2,699.00
▼(-8.17% Downside)
Action:ReiteratedDate:04/25/26
The score is driven primarily by strong underlying profitability and a conservative balance sheet, but is held back by weak recent cash conversion (negative FCF) and a clear technical downtrend. Valuation support (moderate P/E and ~3.1% yield) and an earnings update showing strong product momentum with reiterated guidance partially offset near-term margin and expense pressures.
Positive Factors
High gross margins & improving returns
Sustained high gross margins (high‑70s) and improving returns on equity indicate durable product-level profitability and efficient capital use. This supports long‑term cash generation potential and funding of R&D/expansion even if near‑term operating cash fluctuates.
Negative Factors
Weak cash conversion recently
Negative FCF in FY2025 and slightly negative TTM FCF signal fragile earnings‑to‑cash conversion; persistent working capital swings or heavy capex/R&D could constrain internal funding. This raises reliance on partnerships or external financing for growth investments.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins & improving returns
Sustained high gross margins (high‑70s) and improving returns on equity indicate durable product-level profitability and efficient capital use. This supports long‑term cash generation potential and funding of R&D/expansion even if near‑term operating cash fluctuates.
Read all positive factors
Daiichi Sankyo Company (4568) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥4.84T
Dividend Yield2.07%
Average Volume (3M)6.53M
Price to Earnings (P/E)17.9
Beta (1Y)0.73
Revenue Growth14.26%
EPS Growth27.11%
CountryJP
Employees18,726
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,894,350,600
10 Day Avg. Volume6,968,810
30 Day Avg. Volume6,527,236
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)4.10
Price to Sales (P/S)3.53
P/FCF Ratio-106.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,178.57Price Target Upside42.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Daiichi Sankyo Company Business Overview & Revenue Model
Company Description
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabali...
How the Company Makes Money
Daiichi Sankyo primarily makes money by selling prescription pharmaceuticals. Revenue is generated from (1) product sales in Japan through its domestic commercial operations and (2) overseas product sales through its international subsidiaries and...
Daiichi Sankyo Company Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
84
Very Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.05T | 1.89T | 1.60T | 1.28T | 1.04T | 962.52B |
| Gross Profit | 1.59T | 1.47T | 1.19T | 914.95B | 691.56B | 624.23B |
| EBITDA | 401.46B | 380.57B | 271.13B | 169.72B | 131.27B | 121.18B |
| Net Income | 304.60B | 295.76B | 200.73B | 109.19B | 66.97B | 75.96B |
Balance Sheet | ||||||
| Total Assets | 3.82T | 3.46T | 3.46T | 2.51T | 2.22T | 2.09T |
| Cash, Cash Equivalents and Short-Term Investments | 541.45B | 713.97B | 876.56B | 607.56B | 778.62B | 629.74B |
| Total Debt | 300.55B | 155.89B | 156.00B | 192.86B | 213.62B | 226.17B |
| Total Liabilities | 2.11T | 1.83T | 1.77T | 1.06T | 864.87B | 807.03B |
| Stockholders Equity | 1.71T | 1.62T | 1.69T | 1.45T | 1.35T | 1.27T |
Cash Flow | ||||||
| Free Cash Flow | -10.50B | -62.42B | 510.94B | 53.77B | 76.49B | 160.96B |
| Operating Cash Flow | 123.86B | 53.84B | 599.26B | 114.51B | 139.23B | 192.21B |
| Investing Cash Flow | -192.64B | 334.17B | -282.64B | -257.78B | 212.34B | -39.25B |
| Financing Cash Flow | -58.10B | -377.77B | -123.56B | -89.59B | -86.23B | -202.43B |
Daiichi Sankyo Company Technical Analysis
Positive
2939.00
Price Trends
2866.31
Positive
3107.62
Negative
3317.36
Negative
Market Momentum
-11.12
Negative
56.98
Neutral
72.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4568, the sentiment is Positive. The current price of 2939 is above the 20-day moving average (MA) of 2852.13, above the 50-day MA of 2866.31, and below the 200-day MA of 3317.36, indicating a neutral trend. The MACD of -11.12 indicates Negative momentum. The RSI at 56.98 is Neutral, neither overbought nor oversold. The STOCH value of 72.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4568.
Daiichi Sankyo Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | ¥2.79T | 8.09 | 12.22% | 2.22% | 7.76% | 15.64% | |
77 Outperform | ¥12.99T | 30.70 | 22.23% | 1.17% | 5.65% | 10.24% | |
70 Neutral | ¥8.26T | 18.42 | 0.54% | 4.11% | -2.50% | -45.28% | |
68 Neutral | ¥1.32T | 19.13 | 5.75% | 3.51% | 2.09% | -26.70% | |
67 Neutral | ¥4.14T | 25.93 | 7.97% | 3.61% | 11.87% | 474.27% | |
66 Neutral | ¥4.84T | 17.88 | 18.56% | 2.07% | 14.26% | 27.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4568
Daiichi Sankyo Company
2,596.00
-863.01
-24.95%
JP:4503
Astellas Pharma
2,300.00
957.49
71.32%
JP:4519
Chugai Pharmaceutical Co
7,900.00
-42.22
-0.53%
JP:4523
Eisai Co
4,677.00
754.80
19.24%
JP:4507
Shionogi & Co
3,177.00
823.88
35.01%
JP:4502
Takeda Pharmaceutical Co
5,213.00
1,145.27
28.16%
Daiichi Sankyo Company Corporate Events
Daiichi Sankyo Reports January Progress on Ongoing Share Buyback Program
Feb 2, 2026
Daiichi Sankyo has disclosed the progress of its ongoing share buyback program, reporting the acquisition of 3,403,600 of its own ordinary shares on the Tokyo Stock Exchange between January 1 and January 31, 2026, at a total cost of approximately ...
Daiichi Sankyo Publishes Q3 FY2025 Consolidated Financial Reference Data
Jan 30, 2026
Daiichi Sankyo has released its consolidated financial reference data for the third quarter of fiscal year 2025, providing detailed information on profit or loss, core operating profit adjustments, revenues by global products and business units, a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.